Belgium-based UCB SA has upgraded its medium-term sales forecast for core neurology and immunology products after a year of improved profitability and sales growth. During 2018 the company’s epilepsy product Vimpat (lacosamide) achieved sales of €1.1 billion with double-digit growth in the US, Europe and elsewhere.
